Latest News

 Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows / image courtesy of Karolinska Institutet
Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows

July 2nd 2025

Research from the Karolinska Institute reveals that therapies such as dupilumab and mepolizumab may not eliminate Th2 lymphocytes, raising concerns about long-term remission.

Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data
Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

June 23rd 2025

 / image credit Cathy Goldstein, MD   Courtesy of Michigan Neuroscience Institute
Validation Study of SANSA Home Sleep Apnea Test Published in Frontiers in Neurology, Huxley Medical Announces

June 18th 2025

Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma
Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma

June 17th 2025

Solriamfetol Improves OSA-Related Cognitive Deficits Independent of Sleepiness Reduction
Solriamfetol Improves OSA-Related Cognitive Deficits Independent of Sleepiness Reduction

June 16th 2025

Video Interviews
Podcasts
Latest CME Events & Activities

Tumor Board: Expert Insights on Managing Classical š˜Œš˜Žš˜š˜™ Mutations, š˜Œš˜Žš˜š˜™ Exon 20 Insertions, and Atypical š˜Œš˜Žš˜š˜™ Mutations in Metastatic NSCLC

View More

Medical CrossfireĀ®: Expert Perspectives on Targeting c-Met Overexpression and š˜”š˜Œš˜› Genomic Alterations in NSCLC – Unveiling the Complexities of š˜”š˜Œš˜› Dysregulation

View More

PER Tumor BoardĀ®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

View More

Medical CrossfireĀ®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

View More

Medical CrossfireĀ®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

View More

Top 10 Oncogenic Drivers in NSCLC for 2024: Where Are We and Where Are We Going?

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

DLL3 as a Therapeutic Target in SCLC and Beyond: Rationale, Recent Data and Potential for Transformations in Care with T-Cell Engagers

View More

Lung Cancer Tumor BoardĀ®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?

View More

26th Annual International Lung Cancer CongressĀ®

July 25-26, 2025

Register Now!

Surv.AI Says: Real-World Insights Into the Journey for Patients With Pulmonary Arterial Hypertension

View More

Advances Inā„¢: Moving Care Forward in SCLC with DLL3 Targeting Bispecific T-Cell Engagers

View More

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

View More

What’s Next for HER2- and TROP2-Directed ADCs in Lung Cancer: How Emerging Trial Data will Impact our Clinics Today, and Tomorrow….

View More

Do We Have Sea Change in Small Cell Lung Cancer? What Recent Clinical Trial Data Tell Us About Treatment Decision-Making in Real-World Settings, What’s Next for Emerging Novel Strategies

View More

Community Practice Connectionsā„¢: 25th Annual International Lung Cancer Congress

View More

Community Practice Connectionsā„¢: 8th Annual School of Nursing Oncologyā„¢

View More

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

View More

(CME Credit Only) Lung Cancer Tumor BoardĀ®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

View More

(MOC and CME Credit) Lung Cancer Tumor BoardĀ®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

View More

(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

View More

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

View More

20th Annual New York Lung Cancers SymposiumĀ®

November 15, 2025

Register Now!

Virtual Tumor Board for the Onco-Nurse: Improving Outcomes in SCLC Treatment and AE Management

View More

Cases & Conversationsā„¢: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

View More

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

View More

Burst CMEā„¢: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

View More

Burst CMEā„¢: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

View More

Burst CMEā„¢: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

View More

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Register Now!

More News

Ā© 2025 MJH Life Sciences

All rights reserved.